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Breast carcinoma is the most common cancer and cause of death among females 
worldwide, including Jordan. The risk factors for breast carcinoma are linked to 
DNA mutation and failure of DNA repair or detoxification systems. Identifica-
tion of susceptibility factors that predispose individuals to breast carcinoma if 
they are exposed to particular environmental agents might give further insight 
into the etiology of this malignancy. The glutathione S-transferase (GST) enzyme 
family detoxifies carcinogenic compounds. Several genes that code for these en-
zymes are polymorphic, with particular genotypes previously shown to confer an 
increased carcinoma risk. The present study investigates GST-pi polymorphism in 
100-tissue samples previously diagnosed as breast carcinoma, and in 48 non-cancer 
age-matched breast tissues, using the restriction fragment length polymorphism 
(RFLP) method for the polymerase chain reaction (PCR) product. Among breast 
cancer cases, 58%, 40% and 2% were homozygous (Ile/Ile), heterozygous (Ile/Val) 
and homozygous (Val/Val) respectively. In the control group, 58%, 37.5% and 
4.2% were homozygous (Ile/Ile), heterozygous (Ile/Val), and homozygous (Val/Val) 
respectively. Our results did not support the involvement of GST-pi gene polymor-
phism in susceptibility to breast carcinoma in the tested North Jordanian female 
population. 
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Introduction
Breast carcinoma, in 2007, ranked first among 
cancers in the Jordanian female population and it 
accounted for 35.8% of all female cancers. The crude 
incidence rate for female breast carcinoma in Jordan 
was 29.6 per 100 000 of the female population in 
2007, compared to 25.4 per 100 000 in 2005. Histo-
pathological distribution of female breast carcinomas 
showed that 77.4% were infiltrating ductal carcino-
ma, 7.1% were lobular carcinoma, 1.8% were mixed 
ductal and lobular carcinoma, and the remainder 
were other types of morphology [1].
Identified risk factors of breast carcinoma explain 
only one third of the disease cases. These risk factors 
include age (breast carcinoma incidence increases in 
post-menopausal females), family history of the dis-
ease and several reproductive factors [2]. The disease 
occurs in both sporadic and hereditary forms, the 
latter accounting for about 10% of total cases [3]. 
The cause of breast carcinoma is generally unknown; 
however, it develops when there is loss of control over 
cells of the breast, which multiply rapidly because of 
both genetic and environmental factors [3]. Enzymes 
involved in the detoxification of carcinogenic com-
pounds as well as DNA repair may play a role in the 
susceptibility to this and other forms of cancer. The 
effectiveness of the detoxifying properties of such 
enzymes is genetically determined [4]. Polymorphic 
genes that code for these enzymes may hence be in-
volved in breast carcinoma susceptibility.
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The glutathione S-transferases (GSTs) comprise 
a supergene family of phase-2 enzymes that catalyze 
the detoxification of electrophilic compounds such as 
carcinogens and cytotoxic drugs by glutathione con-
jugation [5, 6]. In addition, they guard DNA from 
damage and adduct formation through conjugation. 
GSTs detoxify the products of oxidation process, car-
ried out by phase 1 enzymes [7]. 
Glutathione S-transferase-pi is a major GST, which 
is expressed in both normal and tumor breast tissue 
[8, 9, 10], and the GST-pi gene has been mapped to 
a small region of chromosome 11q. Polymorphisms 
in exon 5 (Ile105Val) and exon 6 (Ala114Val) of the 
GST-pi gene have been identified [11, 12], and both 
affected codons lie in close proximity to the hydro-
phobic binding site of GST-pi. Moreover, polymor-
phism is known to change the properties of the en-
zyme [7]. The 105Val variant has been demonstrated 
to have either lower or higher specific activity and af-
finity than that of 105Ile depending on the substrate, 
whereas the Ala114Val polymorphism seems not to 
influence enzyme activity [13, 14].
Against this background, the possibility that GST-
pi polymorphism may be involved in the pathogen-
esis of breast carcinoma has received great attention. 
Some epidemiological studies on the potential associ-
ation between genetic polymorphisms of GST-pi and 
breast carcinoma have produced inconsistent results 
[15-18]. These studies consistently failed to detect 
an association between breast carcinoma and GST-pi 
polymorphism, and the results and conclusions have 
been highly variable. These inconsistencies might be 
partly due to differences in populations, and their ex-
posure to factors of breast carcinoma development. 
The evidence regarding a possible association of GST-
pi polymorphism with breast carcinoma is thus con-
troversial and, in view of the high incidence of this 
tumor, requires clarification. 
Based on these considerations, this issue was eval-
uated for the first time in breast carcinoma in a Jor-
danian female population employing a combination 
of methods. All cases were subjected to a polymerase 
chain reaction (PCR) based genotyping assay and 
immunohistochemistry staining. Our data show 
no involvement of this specific GST-pi gene polymor-
phism in susceptibility to breast carcinoma.
Material and methods
This study includes 100 samples of paraffin-em-
bedded tissue blocks of female individuals previous-
ly diagnosed with breast carcinoma, and 48 samples 
of paraffin-embedded breast tissue with no history of 
cancer of any type as a control population. All sam-
ples and the clinical data including age group, type 
of carcinoma, size and grade of carcinoma were 
collected from the medical records and the Pathol-
ogy Department at Jordan University of Science and 
Technology. All samples were stored at room tem-
perature. 
The median age of the cancer patients was 44.66 
years (range, 20 to 75 years). Node involvement was 
detected in 18% of cases. The tumor size was < 1 cm 
in diameter in 6% of cases, > 1 and < 3 cm in 40% 
of cases, and >3 cm in 54% of cases. Tumor type was 
ductal in 88% of cases, lobular in 6%, and of oth-
er types in 6%. The distribution of histoprognostic 
grading was 10% for type I, 40% for type II, and 
50% for type III (Table I).
The control population includes 20 fibroadeno-
mas, 8 fibrocystic changes, 8 duct ectasias, 4 scle-
rosing adenosis, 4 hyperplasias, and 4 intraductal 
papillomas. The median age of the control group was 
37.6 years (range, 20 to 56 years). The size of benign 
lesions ranged from 1 to 2 cm in diameter, which was 
obtained by open surgical biopsy due to the fear of 
hidden microscopic cancer.
Immunohistochemistry (IHC) 
Sections of 4 μm were cut from paraffin blocks 
(from representative tumor samples excluding lymph 
nodes and necrotic sections of the primary tumor 
and from specimens of the control group). All paraf-
fin sections were mounted on coated slides and were 
dewaxed in xylene, rehydrated through a series of 
graded alcohol, placed in 10 mM citrate buffer (pH 
6.0) and submitted to heat retrieval for 6 min. After 
heating, the slides were allowed to cool to room tem-
perature and washed with phosphate-buffered saline 
(PBS). Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide in methanol for 5 min. 
Table I. Pathologic and clinical data of patients with 
breast cancer 
clinico-Pathological factors number 
of Patients
Patient age < 50 years 34 (34%)
> 50 years 66 (66%)
Size of primary 
tumor
< 1 cm 6 (6%)
1-3 cm 40 (40%)







ductal carcinoma 88 (88%)
lobular carcinoma 6 (6%)
others 6 (6%)
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Serum-free protein block (Dako, Denmark) was used 
for 5 min in order to block nonspecific immunoreac-
tions. Monoclonal antibody against GSTPi (Abnova, 
Taiwan) was diluted 1 : 50 in antibody diluent and 
was applied to all slides for 30 min at room tempera-
ture. Detection was performed using the Dako Envi-
sion Dual Link system (Dako, Denmark) according 
to the manufacturer’s instructions. After that, slides 
were visualized using Dako liquid DAB (Dako, Den-
mark). Mayer’s hematoxylin was applied as a count-
er stain. The positive control for GST-pi was a slide 
containing normal breast tissue run simultaneously 
with the samples. As a negative control, the primary 
antibodies were omitted. In addition, the tumor tis-
sue was compared with the adjacent normal tissue as 
available. Tumors were considered positive for GST-
pi if more than 1% of the neoplastic cells displayed 
a distinct brown staining. The slides were scanned 
and all cells were counted in a high power field. 
Images were photographed using a digital camera 
(Olympus model C-5060). 
DNA extraction
DNA from 10 μm sections of paraffin-embedded 
tissue blocks belonging to all cases (cancer and con-
trols) was extracted with an EXTRAffin kit (Nano-
gen Advanced Diagnostics S.r.L., Buttigliera Alta, 
Italy) according to the manufacturer’s instructions. 
The extraction product was stored at –20°C.
Genotyping
The polymorphism (Ile 105 → Val) in the exon 5 co- 
ding region of the GST-pi gene was detected by re-
striction fragment length polymorphism of PCR am-
plified fragments. Standard GST-pi primers (forward 
5′– ACC CCA GGG CTC TAT GGG AA–3′, and 
reverse 5′–TGA GGG CAC AAG AAG CCC CT–3′) 
(Alpha DNA, Canada) were used for the amplifica-
tion reactions and restriction enzyme corresponding to 
RFLP (Fermentas, Canada) for the digestion reactions. 
PCR reactions were carried out in a 30-μl volume 
containing about 5 μL of genomic DNA template, 
PCR master mix (200 μM each dNTP, 1.5 mM MgCl2, 
1× PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 
8.3)] and 2 unit Taq DNA polymerase) (Promega, 
USA) and 200 ng of each primer. After an initial de-
naturation step of 5 min at 95°C, the samples were 
processed through 35 temperature cycles of 30 s at 
94°C, 1 minute at 59°C, and 1 minute at 72°C. After 
a final extension step of 72°C for 10 min, the presence 
of successful amplification was confirmed by electro-
phoreses on 2% agarose gel. The 176-bp PCR prod-
ucts (10 μl) were digested overnight at 55°C with 
5 units of BsmA1 restriction enzyme. The detection 
of the different alleles was carried out by horizontal 
ethidium bromide 4% agarose gel electrophoresis, 
along with a 100-bp DNA ladder. Genotypes were 
determined as homozygous for the wild type allele 
(Ile/Ile; 176 bp), heterozygous (Ile/Val; 176, 91, 85 
bp) or homozygous for the mutant allele (Val/Val; 91, 
85 bp). 
Statistical analyses
All statistical analyses were performed using Epi-
Info version 6. Chi-square test was used to determine 
if there are any significant differences in polymor-
phism frequencies in the cancer cases compared with 
the control population. Statistics were calculated us-
ing 95% confidence intervals (p < 0.05 significant). 
Results
PCR-based genotyping assay was used to examine 
a GST-pi polymorphism in breast carcinoma suscep-
tibility. The genotypic results of GST-pi are presented 
in Table II and Fig. 1. Our results showed no gen-
otype effect with GST-pi genotype. Among breast 
cancer patients, 58% were homozygous for the wild 
type allele (Ile/Ile), 40% were heterozygous (Ile/Val) 
and 2% homozygous for the mutant allele (Val/Val). 
In the control group, 58% of the subjects were homo-
zygous for the GST-pi wild type allele, 37.5% were 
heterozygous and 4.2% homozygous for the mutant 
allele (Table II). A slight difference was shown not to 
be significantly different. Overall, the results indicate 
that these GST-pi types do not appear to influence 
breast cancer susceptibility in the tested Jordanian fe-
male population. The observed percentages of GST-
pi wild type and GST-pi mutant alleles were 77.1% 
and 22.9%, respectively in the control population. 
In the 100 breast cancer population cases, the cor-
responding frequencies of GST-pi alleles were 78% 
and 22%, for GST-pi wild type and mutant alleles, 
respectively (Table II). 
On the subject of immunohistochemistry, there 
were 58% GST-pi positive breast tumors; 38 and 20 
cases of them were homozygous for the wild type al-
lele (Ile/Ile) and heterozygous (Ile/Val) respectively. 
GST-pi protein was expressed in the cytoplasm, the 
nucleus, or both (Fig. 2). The proportion of GST-pi 
positive tumors was not significantly correlated with 
any genotype or histologic factors traditionally used 
for prognosis. 
Discussion
Environmental carcinogen and reactive oxygen 
species can interact with DNA, mutate it and pre-
dispose to cancer [19]. An increasing number of 
studies have shown that the ability of individuals to 
detoxify potential carcinogens differs greatly [20]. 
Genes encoding enzymes involved in detoxification 
and metabolism of carcinogens can undergo muta-
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tion leading to different levels of enzyme activity. 
Genetic polymorphisms in these genes are hence 
a factor involved in cancer susceptibility [5, 15]. 
Glutathione-S-transferases are phase II detoxifica-
tion enzymes involved in the metabolism of a wide 
verity of potential carcinogens. The GST-pi variant 
genotype was seen in increased numbers of tumors 
of the kidney, bladder, pancreas and lung [21-23]. 
Millar et al. (1999) showed that the mutated enzyme 
(valine genotype) has lowered activity toward its sub-
strate. The GST-pi polymorphism results in an amino 
acid change from isoleucine (wild type) to a valine 
(variant); this amino acid substitution occurs in the 
active site of the enzyme, which introduces confor-
mational changes, due to the bulky properties of the 
valine side chain. Therefore, it is reasonable to spec-
ulate that a carcinogen metabolizing enzymes with 
lower activity could be associated with an elevated 
risk of developing cancer. However, to date, the po-
Table II. Genotype and allele percentage of the GSTP1 polymorphism 
Patients (n = 100) control (n = 48) P value
genotyPe number Percentage number Percentage
Ile/Ile 58 58% 28 58.33% 0.97
Ile/Val 40 40% 18 37.5%
Val/Val 2 2% 2 4.16%
allele number of 
alleles in 100 
cancer cases 
Percentage of 
alleles in 100 
cancer cases
number of 
alleles in 48 
controls 
Percentage of 
alleles in 48 
controls
Ile 156 78% 74 77.1%
Val 44 22% 22 22.9%
Fig. 2. Cytoplasmic and nuclear immunohistochemical 
staining of GST-pi enzyme in malignant glandular epithe-
lium of the breast. Magnification 20× 
Fig. 1. Gel electrophoresis of GSTP1 RFLP results. Lane 2, 4, 6, 8, 10, 12 undigested samples, lane 3, 5, 7, 9, 11, 13 
digested sample with BsmA1
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tential association between genetic polymorphisms of 
GST-pi and breast carcinoma is still somewhat contro-
versial and may vary from population to population 
[15-18, 25-31].
In the present study, GST-pi overexpression was 
detected in 58% of the examined breast cancer tis-
sues. This finding is similar to that reported in Cau-
casian populations [32-34]. The absence of GST-pi 
protein in the remaining homozygous wild type al-
lele breast tumors could be due to epigenetic mod-
ification such as DNA methylation and chromatin 
remodeling.
The statistical analysis of the presence of mutant 
allele showed no significant relationship between ho-
mozygous mutants and/or the heterozygous mutant 
and increased risk of breast cancer (Table II). The 
GST-pi wild type allele was present in 78% of the 
cancer samples, and in 77.1% of the control samples. 
Hence, the isoleucine allele does not appear to have 
a protective effect against breast cancer development. 
On the other hand, the mutant allele was present in 
42% of breast cancer cases, and in 41.7% of controls. 
These results indicate that there is no correlation be-
tween the presence of the mutant allele and increased 
risk of breast cancer. This suggests that the mutant 
allele is randomly distributed in cancer and control 
cases. Our results are in harmony with the findings of 
many other reports such as those of Vogl et al. (2004) 
[35], and Unlu et al. (2008) [36]. 58.3% of the con-
trols of the present study showed homozygosity for 
the GST-pi wild type allele, which was comparable 
to 56%, 39%, and 64.3% previously reported for 
a female control population from France, Southern 
Taiwan, and Norway respectively [37-39].
The results we report show a lack of association 
between the valine allele and/or variant genotype 
and sporadic breast carcinoma development. Similar-
ly, the frequencies of carriers of the isoleucine allele 
were not different between the populations. Hence, 
in this population the isoleucine allele does not ap-
pear to have a protective effect against breast carci-
noma development. The results of the current study 
have shown that the genotype GST-pi alone is not 
involved in breast carcinoma development, but this 
does not exclude interactions between genes and pos-
sible combinations of genotypes. 
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